Arcus Biosciences, Inc. RCUS
- Market cap
- $3.2B
- P/E
- 0.0×
Follow RCUS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 9.17 | 6.30 | 8.55 | 22.36 | 16.74 | 12.95 | 13.52 | 6.50 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | 22.10 | 13.66 | 37.41 | 49.10 | 42.05 | 25.47 | 20.31 | 26.40 |
High Price
|
|||
| — | — | 108 | 139 | 236 | 366 | 500 | 577 | 627 | 601 |
Employees
|
|||
| — | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | 1 | 8 | 15 | 78 | 383 | 112 | 117 | 258 | 247 |
Revenue
|
|||
| 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| (18) | (53) | (50) | (85) | (123) | 55 | (266) | (301) | (282) | (353) |
EBT
|
|||
| 0.00% | (3,756.69%) | (593.73%) | (564.73%) | (157.69%) | 14.36% | (237.50%) | (257.26%) | (109.30%) | (142.91%) |
EBT Margin
|
|||
| (18) | (53) | (50) | (85) | (123) | 53 | (267) | (307) | (283) | (353) |
Net Income
|
|||
| 1 | 3 | 2 | 1 | 3 | 9 | 6 | (11) | (15) | (3) |
Depreciation
|
|||
| 0.00 | 0.77 | 0.24 | 0.34 | 1.42 | 5.53 | 1.56 | 1.58 | 2.86 | 2.30 |
Revenue/Sh
|
|||
| (20.80) | (29.04) | (1.43) | (1.93) | (2.24) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
Earnings/Sh
|
|||
| (14.98) | (13.71) | (1.24) | (1.68) | 2.03 | (3.69) | 6.08 | (4.14) | (1.89) | (4.49) |
Cash Flow/Sh
|
|||
| (4.74) | (3.02) | (0.11) | (0.04) | (0.05) | (0.38) | (0.08) | (0.32) | (0.07) | (0.02) |
Capex/Sh
|
|||
| (19.73) | (16.72) | (1.35) | (1.72) | 1.97 | (4.07) | 6.00 | (4.46) | (1.95) | (4.51) |
Free CF/Sh
|
|||
| 0.00 | 84.17 | 6.79 | 3.74 | 9.17 | 12.15 | 9.13 | 6.24 | 5.38 | 5.88 |
Book Value/Sh
|
|||
| 1 | 2 | 35 | 44 | 55 | 69 | 72 | 74 | 90 | 107 |
Shares
|
|||
| — | 0.00 | 0.00 | 0.00 | 0.00 | 58.65 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | 0.00 | 44.64 | 29.51 | 18.24 | 7.32 | 12.99 | 12.45 | 5.20 | 10.36 |
PS Ratio
|
|||
| — | 0.00 | 1.59 | 2.70 | 2.83 | 3.33 | 2.21 | 3.15 | 2.77 | 4.06 |
PB Ratio
|
|||
| — | 0.00 | 13.92 | 16.96 | 9.09 | 6.33 | 5.02 | 6.96 | 1.60 | 6.79 |
EV/Sales
|
|||
| — | 4.73 | (2.49) | (3.37) | 6.56 | (8.59) | 1.30 | (2.47) | (2.34) | (3.47) |
EV/FCF
|
|||
| (13) | (25) | (43) | (73) | 111 | (256) | 438 | (306) | (170) | (482) |
Op' Cash Flow
|
|||
| (4) | (6) | (4) | (2) | (3) | (26) | (6) | (24) | (6) | (2) |
Capex
|
|||
| (17) | (31) | (47) | (75) | 108 | (282) | 432 | (330) | (176) | (484) |
FCF
|
|||
| 94 | 164 | 242 | 170 | 614 | 1,096 | 874 | 647 | 790 | 776 |
Working Cap'
|
|||
| — | — | — | — | 15 | 117 | 117 | — | 48 | 99 |
Total Debt
|
|||
| (99) | (176) | (257) | (188) | (714) | (382) | (892) | (759) | (930) | (882) |
Net Debt
|
|||
| 0 | 154 | 235 | 164 | 502 | 842 | 657 | 462 | 485 | 631 |
Sh' Equity
|
|||
| (18.92%) | (55.73%) | (21.31%) | (35.44%) | (25.22%) | 4.48% | (18.18%) | (25.16%) | (25.21%) | (30.84%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.34% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| 39.07% | 114.99% | (61.00%) | (42.48%) | (36.93%) | 7.89% | (35.62%) | (54.87%) | (59.77%) | (63.26%) |
ROE
|
|||
Arcus Biosciences, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DYN Dyne Therapeutics, Inc. | $3.1B | 0.0× | Compare |
| ELVN Enliven Therapeutics, Inc. | $3.3B | 0.0× | Compare |
| DNLI Denali Therapeutics Inc. | $3.4B | 0.0× | Compare |
| ARQT Arcutis Biotherapeutics, Inc. | $3.4B | 122× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IDYA IDEAYA Biosciences, Inc. | $3.6B | 0.0× | Compare |
| TARS Tarsus Pharmaceuticals, Inc. | $3.6B | 0.0× | Compare |
| ZLAB Zai Lab Limited Unsponsored ADR | $2.9B | 0.0× | Compare |
| PGEN Precigen, Inc. | $2.8B | 0.0× | Compare |
Arcus Biosciences, Inc. (RCUS) key facts
- Arcus Biosciences, Inc. (RCUS) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Arcus Biosciences, Inc. reported a net loss of $353.0 million, or a loss of $3.29 per share, for fiscal 2025.
- As of September 25, 2026, RCUS traded at $24.97, a market capitalization of $3.2 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 26.7× sales.
- Return on equity was −63.3% and debt-to-equity 0.22.
Arcus Biosciences, Inc. (RCUS) Latest News
22 Sep
Arcus Biosciences will host an in-person investor event with a live webcast on October 20, 2026, in New York City to present ARC-20 data on casdatifan, a next-generation HIF-2α inhibitor, across first-, second-, and late-line ccRCC. Presenters include Arcus management and UCSD's Dr. Rana McKay. Data include: first-line TKIs-free combinations—casdatifan + zimberelimab (safety and early efficacy in ~30 patients) and casdatifan + ipilimumab + zimberelimab (safety in ~20 patients) supporting PEAK-20 (casdatifan + ipilimumab + nivolumab) planned for Q4 2026. Second-line: casdatifan + cabozantinib in 43 patients with ORR, PFS, and early OS data; late-line monotherapy: casdatifan OS and updated ORR/PFS in 121 patients (~28 months). Subgroup analyses and translational PD markers linking HIF-2α inhibition with OS will be presented. Taiho holds Asia rights; Arcus retains global rights. Replay will be on the Arcus site. Multiple first-, second-, and late-line data plus planned registrational trials could materially boost Arcus’s value and strategic position, though approvals remain uncertain.
13 Aug
Arcus Biosciences partners with Summit Therapeutics on a cancer drug that may establish a new treatment standard. Cancer drug partnership with Summit represents major strategic move likely to significantly alter RCUS trajectory.
12 Aug
Arcus Biosciences (RCUS) released its Q2 2026 earnings call transcript covering quarterly financial results and business updates. Earnings call provides standard quarterly updates on financials and operations with moderate potential to shift near-term sentiment.
10 Aug
Morgan Stanley projects Arcus Biosciences' Casdatifan therapy launch in 2028. Casdatifan launch projection signals major pipeline advancement for RCUS.
8 Aug
Arcus Biosciences reported Q2 financial results and pipeline updates in its earnings call, covering oncology programs, partnerships, cash position and upcoming milestones. Earnings call delivered pipeline and financial updates that may affect near-term sentiment but lack transformative announcements.
Arcus Biosciences (RCUS) stock receives fair value increase on optimism for Casdatifan. Casdatifan optimism triggers fair value upgrade affecting RCUS stock trajectory.
6 Aug
Arcus Biosciences reported Q2 2026 financial results and pipeline updates during its earnings call. Quarterly earnings provide financial metrics and pipeline status that moderately influence near-term stock movement.
5 Aug
Arcus Biosciences reported second-quarter 2026 financial results and provided a pipeline update. Quarterly results combined with pipeline updates typically produce moderate effects on valuation and near-term sentiment.
23 Jul
SMMT released updated survival data for Ivonescimab from its NSCLC study. Positive competitor survival data may affect RCUS NSCLC program positioning.
22 Jul
Arcus Biosciences enters clinical supply agreement with AVEO Oncology to evaluate casdatifan combined with tivozanib in advanced kidney cancer patients. Clinical supply agreement enables pipeline evaluation of combination therapy with moderate effect on development progress.
Arcus Biosciences and Summit Therapeutics entered a clinical trial collaboration to evaluate Casdatifan combined with Ivonescimab in kidney cancer. Partnership enables expanded testing of Casdatifan in kidney cancer but remains an early-stage trial agreement without immediate financial or approval impact.
Arcus Biosciences and Summit Therapeutics enter clinical trial collaboration to evaluate Casdatifan combined with Ivonescimab in kidney cancer. Collaboration initiates kidney cancer trial for Casdatifan, advancing pipeline and competitive positioning with moderate long-term effects.
1 Jul
Bristol-Myers Squibb partners with Arcus Biosciences to test a new two-drug kidney cancer combination. Partnership with Bristol-Myers Squibb advances Arcus kidney cancer pipeline and strengthens competitive position.
New research published in Nature links Casdatifan's clinical activity to HIF-2a biology in advanced kidney cancer patients. Prestigious Nature publication validating Casdatifan mechanism strengthens RCUS development path and investor outlook.
4 Jun
Arcus Biosciences partners with Bristol Myers Squibb to advance a kidney cancer clinical study. Bristol Myers Squibb collaboration directly advances Arcus kidney cancer program with major clinical and market upside.
3 Jun
Arcus Biosciences announces clinical trial collaboration and supply agreement to evaluate casdatifan in combination with PD-L1/VEGF-A bispecific immunomodulator for kidney cancer treatment. Trial collaboration advances kidney cancer combination therapy evaluation and oncology pipeline development.
8 May
Analysts updated estimates for Arcus Biosciences (NYSE:RCUS) after its first-quarter report, with brokers sharing views on future performance. Post-Q1 analyst estimate revisions signal moderate shifts in earnings forecasts, likely influencing financial performance and investor sentiment.
6 May
Arcus Biosciences rethinks growth strategy after exiting STAR-121 program and shifting partnership with Gilead. STAR-121 exit and Gilead partnership shift represent major strategic changes likely to significantly alter Arcus Biosciences' trajectory and investor sentiment.
5 May
Arcus Biosciences (RCUS) Q1 2026 earnings call transcript details quarterly financial results, pipeline updates, and forward guidance. Q1 2026 earnings transcript reveals financial performance, clinical progress, and strategic plans impacting RCUS stock trajectory.
Arcus Biosciences, Inc. (RCUS) released Q1 2026 earnings call summary detailing financial results, pipeline progress, clinical trial updates, and strategic priorities. Q1 2026 earnings summary provides updates on financials and pipeline that moderately influence investor sentiment and stock performance.
Arcus Biosciences reported first-quarter 2026 financial results and provided a pipeline update. Quarterly financial results and pipeline updates moderately affect financial performance and investor sentiment.
28 Apr
Arcus Biosciences, Inc. (RCUS) may report negative earnings next week, with analysis highlighting the ongoing trend for investors ahead of the release. Expectation of negative earnings directly affects financial performance and could moderately sway investor sentiment ahead of the report.
25 Apr
Arcus Biosciences (RCUS) stock rose 5.2% after futility results from a Phase 2 lung cancer trial and a shift in Gilead's option under their collaboration. Futility in lung cancer trial alongside Gilead option shift marks major pipeline setback and partnership evolution with strong market reaction.
24 Apr
Gilead pulls back from Arcus Biosciences (RCUS) amid challenges with Idvynso HIV drug, potentially shifting the investment case for GILD and impacting RCUS's partnership-driven growth. Gilead's strategic pullback from Arcus reduces critical partnership funding and support for RCUS's pipeline, significantly threatening its market performance.
2 Mar
Arcus Biosciences positions casdatifan kidney cancer data as its primary focus, spotlighting the investigational HIF-2a inhibitor's Phase 3 results and potential in renal cell carcinoma treatment. Highlighting casdatifan data represents a major strategic emphasis on a lead oncology asset, likely driving positive shifts in pipeline perception and investor sentiment for RCUS.
28 Feb
Arcus Biosciences released Q4 earnings call highlights detailing financial results, pipeline updates, and strategic priorities. Q4 earnings highlights disclose financial performance and clinical progress pivotal to investor confidence and stock trajectory.
26 Feb
Arcus Biosciences, Inc. (RCUS) released Q4 2025 earnings call summary covering financial results, clinical pipeline progress, strategic partnerships, and 2026 outlook. Q4 earnings call summaries disclose critical financials, pipeline advancements, and guidance that significantly shape investor sentiment and company trajectory.
Arcus Biosciences Inc (RCUS) Q4 2025 earnings call highlights strong cash position supporting ongoing operations and development pipeline. Strong cash position bolsters financial runway for clinical programs and positively influences investor sentiment and stock trajectory.
25 Feb
Arcus Biosciences (RCUS) Q4 2025 earnings call transcript details financial results, clinical pipeline progress, strategic partnerships, and forward guidance. Q4 earnings call transcript provides key financial metrics, pipeline advancements, and outlook that significantly shape investor expectations and stock trajectory.
Arcus Biosciences reported fourth-quarter and full-year 2025 financial results alongside a pipeline update. Quarterly earnings and pipeline updates moderately affect financial performance and investor sentiment in biotech.